A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years

Part of paid clinical trials in Lincoln, Nebraska.

Sponsor
Centessa Pharmaceuticals (UK) Limited
Study ID
NCT07413666
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Adult Male and Female Volunteers

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • ORX489 Tablets — DRUG
    ORX489 Tablets
  • Placebo Tablets — OTHER
    Placebo Tablets

Study Details

Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.

Key Dates

Start date
Feb 25, 2026
Status verified
Feb 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
212 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Part A
    SAD Study in Healthy Adults: ORX489 and Placebo
  • Experimental: Part B
    Food-effect Evaluation in Healthy Adults: ORX489
  • Experimental: Part C
    MAD Study in Healthy Adults: ORX489 and Placebo
  • Experimental: Part D
    SAD Study in Acutely Sleep-Deprived Healthy Adults: ORX489 and Placebo

Primary Outcome Measure

Part A [ Time Frame: From enrollment to the Follow-Up Visit 7 days post-discharge ]

Central Contacts

  • ORX489 Centessa Program Lead ORX489 Centessa Program Lead
    617-468-5770
    [email protected]
  • Celerion Program Lead CA49982 United States, Nebraska [Recruiting]

Locations (1)

FacilityCityStateZIPSite coordinators
CelerionLincolnNebraska68502-

Find similar trials in Lincoln, NE

By research site
Celerion· Lincoln, NE

Related Studies